A multi-center, randomized, double-blind phase II study comparing temozolomide (TMZ) plus either veliparib (ABT-888), a PARP inhibitor, or placebo as 2nd or 3rd-line therapy for patients (Pts) with relapsed small cell lung cancers (SCLCs) Meeting Abstract
| Authors: | Pietanza, M. C.; Krug, L. M.; Waqar, S. N.; Dowlati, A.; Hann, C. L.; Chiappori, A.; Owonikoko, T. K.; Woo, K.; Bensman, Y.; Hurtado, B.; Fujimoto, J.; Wistuba, I. I.; Travis, W. D.; Chen, A. P.; Heymach, J.; Kris, M. G.; Fleisher, M.; Rudin, C. M.; Byers, L. A. |
| Abstract Title: | A multi-center, randomized, double-blind phase II study comparing temozolomide (TMZ) plus either veliparib (ABT-888), a PARP inhibitor, or placebo as 2nd or 3rd-line therapy for patients (Pts) with relapsed small cell lung cancers (SCLCs) |
| Meeting Title: | 52nd Annual Meeting of the American Society of Clinical Oncology (ASCO) |
| Journal Title: | Journal of Clinical Oncology |
| Volume: | 34 |
| Issue: | 15 Suppl. |
| Meeting Dates: | 2016 Jun 3-7 |
| Meeting Location: | Chicago, IL |
| ISSN: | 0732-183X |
| Publisher: | American Society of Clinical Oncology |
| Date Published: | 2016-05-20 |
| Start Page: | 438s |
| Language: | English |
| ACCESSION: | WOS:000404711505244 |
| DOI: | 10.1200/JCO.2016.34.15_suppl.8512 |
| PROVIDER: | wos |
| Notes: | Meeting Abstract: 8512 -- Source: Wos |
